Patents by Inventor Todd C. Zankel

Todd C. Zankel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Thiol Compounds to Treat Neurological Disease
    Publication number: 20230115413
    Abstract: The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.
    Type: Application
    Filed: April 1, 2022
    Publication date: April 13, 2023
    Inventors: Todd C. Zankel, Sara Louise Isbell
  • ADO-resistant cysteamine analogs and uses thereof
    Patent number: 11505550
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: November 22, 2022
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF
    Publication number: 20220024920
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Application
    Filed: February 1, 2021
    Publication date: January 27, 2022
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Methods of Treating Excitotoxicity Disorders
    Publication number: 20210113496
    Abstract: The present disclosure relates in general to methods for the treatment of excitotoxicity disorders, using compositions comprising cysteamine or cystamine or salts or derivatives thereof in combination with an agent that inhibits or blocks glutamate/cystine antiporter xc?.
    Type: Application
    Filed: April 25, 2019
    Publication date: April 22, 2021
    Inventors: Todd C. Zankel, Amanda Anne Ko, Sara Louise Isbell
  • Use of Thiol Compounds to Treat Neurological Disease
    Publication number: 20210069129
    Abstract: The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.
    Type: Application
    Filed: June 23, 2020
    Publication date: March 11, 2021
    Inventors: Todd C. Zankel, Sara Louise Isbell
  • ADO-resistant cysteamine analogs and uses thereof
    Patent number: 10906904
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 2, 2021
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Fucosidase inhibitors
    Patent number: 10308607
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 4, 2019
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • FUCOSIDASE INHIBITORS
    Publication number: 20190077756
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Application
    Filed: March 30, 2018
    Publication date: March 14, 2019
    Applicant: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • Use of Thiol Compounds to Treat Neurological Disease
    Publication number: 20190029977
    Abstract: The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.
    Type: Application
    Filed: April 24, 2018
    Publication date: January 31, 2019
    Inventors: Todd C. Zankel, Sara Louise Isbell
  • COMPOSITIONS COMPRISING RECEPTOR-ASSOCIATED PROTEIN (RAP) VARIANTS SPECIFIC FOR CR-CONTAINING PROTEINS AND USES THEREOF
    Publication number: 20180118802
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: December 13, 2017
    Publication date: May 3, 2018
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Fucosidase inhibitors
    Patent number: 9951013
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: April 24, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
    Patent number: 9879064
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 30, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Todd C. Zankel, Christopher M. Starr
  • FUCOSIDASE INHIBITORS
    Publication number: 20170029376
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Application
    Filed: August 1, 2016
    Publication date: February 2, 2017
    Applicant: RAPTOR PHARMACEUTICALS INC.
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF
    Publication number: 20170002004
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Application
    Filed: July 5, 2016
    Publication date: January 5, 2017
    Applicant: RAPTOR PHARMACEUTICALS INC.
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof
    Publication number: 20160024172
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: June 23, 2015
    Publication date: January 28, 2016
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
    Patent number: 9062126
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: June 23, 2015
    Assignee: RAPTOR PHARMACEUTICALS INC.
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases
    Publication number: 20150125526
    Abstract: The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Patrice Rioux, Todd C. Zankel
  • Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
    Patent number: 8877714
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: November 4, 2014
    Assignee: Raptor Pharmaceutical Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • Treatment of liver disorders by administration of RAP conjugates
    Patent number: 8795627
    Abstract: The present invention relates to the use of receptor-associate protein (RAP) and fragments and variants thereof to improve delivery of therapeutic compounds to the liver and provides methods to treat liver disorders and conditions, such as hepatic carcinoma, by administering RAP or RAP variants conjugated to active agents.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: August 5, 2014
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • Megalin-based delivery of therapeutic compounds to the brain and other tissues
    Patent number: 8609103
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 17, 2013
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Todd C. Zankel, Christopher M. Starr